Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 0 PB Ratio: 1.80 GF Score: 77/100

Q2 2020 Astellas Pharma Inc Earnings Call Transcript

Oct 31, 2019 / 05:00AM GMT
Release Date Price: $17.26 (+1.77%)
Kenji Yasukawa
Astellas Pharma Incorporated - President & CEO

Good afternoon, ladies and gentlemen. Today, thank you very much for coming to our meeting for us to announce our second-quarter financial results. So let me go into my presentation without any further ado. Page 2 is a cautionary statement, as [already] explained, so let me skip. Page 3, this is the agenda for today in my presentation.

Page 4, this slide gives you an overview of the consolidated results on a core basis. Revenues increased to JPY650.5 billion, up 0.5% year-on-year. Core operating profits rose to JPY168 billion, up 8.9% year-on-year. Core profits were JPY135.9 billion, up 8.9% year-on-year. Core EPS rose by 12.8%.

Next page please. This slide shows the year-on-year revenue analysis. The top, JPY647.1 billion, and the four lines beneath. As you can see there, sales of major products increased year-on-year. XTANDI, XOSPATA, mirabegron, global products had increased sales and Evenity launched in March and new product in Japan contributed to increased sales.

On the other hand, in the United States

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot